| Preclinical evaluation of efficacy and safety of an improved lentiviral vector for the treatment of β-thalassemia and sickle cell disease O Negre, C Bartholomae, Y Beuzard, M Cavazzana, L Christiansen, ... Current gene therapy 15 (1), 64-81, 2015 | 135 | 2015 |
| Current and future alternative therapies for beta-thalassemia major E de Dreuzy, K Bhukhai, P Leboulch, E Payen biomedical journal 39 (1), 24-38, 2016 | 113 | 2016 |
| EDIT-301: An Experimental Autologous Cell Therapy Comprising Cas12a-RNP Modified mPB-CD34+ Cells for the Potential Treatment of SCD E De Dreuzy, J Heath, JA Zuris, P Sousa, R Viswanathan, S Scott, ... Blood, The Journal of the American Society of Hematology 134 (Supplement_1 …, 2019 | 29 | 2019 |
| Ex Vivo selection of transduced hematopoietic stem cells for gene therapy of β-hemoglobinopathies K Bhukhai, E De Dreuzy, M Giorgi, C Colomb, O Negre, M Denaro, ... Molecular Therapy 26 (2), 480-495, 2018 | 18 | 2018 |
| Transplantation of Macaca cynomolgus iPS-derived hematopoietic cells in NSG immunodeficient mice S Abed, A Tubsuwan, P Chaichompoo, IH Park, A Pailleret, A Benyoucef, ... haematologica 100 (10), e428, 2015 | 16 | 2015 |
| Preclinical Development of EDIT301, an Autologous Cell Therapy Comprising AsCas12a-RNP Modified Mobilized Peripheral Blood-CD34+ Cells for the Potential Treatment of … P Sousa, T Janoudi, E deDreuzy, MS Shearman, K Zhang, KH Chang Blood 138, 1858, 2021 | 7 | 2021 |
| GENOME EDITING OF HBG1/2 PROMOTER LEADS TO ROBUST HBF INDUCTION IN VIVO, WHILE EDITING OF BCL11A ERYTHROID ENHANCER RESULTS IN ERYTHROID DEFECTS: PS1518 J Heath, E de Dreuzy, M Sanchez, S Haskett, T Wang, P Sousa, G Gotta, ... HemaSphere 3, 699-700, 2019 | 7 | 2019 |
| Comparative Studies Reveal Robust HbF Induction By Editing of HBG1/2 Promoters or BCL11A Erythroid-Enhancer in Human CD34+ Cells but That BCL11A Erythroid-Enhancer Editing Is … KH Chang, M Sanchez, J Heath, E deDreuzy, S Haskett, A Vogelaar, ... Blood 132 (Supplement 1), 409-409, 2018 | 7 | 2018 |
| Robust Pre-Clinical Results and Large-Scale Manufacturing Process for Edit-301: An Autologous Cell Therapy for the Potential Treatment of SCD E De Dreuzy, J Heath, P Sousa, T Janoudi, H An, S Hansen, DK Wood, ... Blood 136 (Supplement 1), 45-46, 2020 | 6 | 2020 |
| Systems and methods for the treatment of hemoglobinopathies EA De Lamothe-Dreuzy, K Chang, J HEATH US Patent App. 17/298,514, 2022 | 3 | 2022 |
| Expanding CRISPR genome editing strategies in hematopoietic stem and progenitor cells for the treatment of hematologic diseases E deDreuzy, A Chalishazar, J Heath, CM Margulies, J Labella, ... Blood 130 (Supplement 1), 4619-4619, 2017 | 2 | 2017 |
| Systems and methods for the treatment of hemoglobinopathies JL Gori, EA De Lamothe-Dreuzy, J HEATH, JA Zuris, K Chang US Patent 12,031,132, 2024 | 1 | 2024 |
| CRISPR/RNA-guided nuclease systems and methods EA De Lamothe-Dreuzy, J HEATH, JL Gori, L Barrera US Patent 11,963,982, 2024 | 1 | 2024 |
| CCTx-001 CAR T-cells targeting the AML specific antigen IL-1RAP show robust pre-clinical anti-tumor efficacy E De Dreuzy, SRE Sayed, D Genin, C Primus, L Bouquet, A Collette, ... Cancer Research 84 (6_Supplement), 6322-6322, 2024 | 1 | 2024 |
| ADV101, a first-in-class IL-1RAP ADC demonstrates significant anti-tumor activity in solid tumor models RCA Sainson, L Demolis, E De Dreuzy, O Favre-Bulle, A Collette, ... Cancer Research 84 (6_Supplement), 2360-2360, 2024 | 1 | 2024 |
| Systems and methods for the treatment of hemoglobinopathies JL Gori, EA De Lamothe-Dreuzy, J HEATH US Patent App. 17/019,126, 2022 | 1 | 2022 |
| Systems and methods for the treatment of hemoglobinopathies EA De Lamothe-Dreuzy, K Chang, ME SANCHEZ, J HEATH US Patent App. 17/013,420, 2021 | 1 | 2021 |
| Potent HbF induction following ssODN-mediated repair of Cas9-induced DSB at the HBG promoter in CD34+ HSPC E De Dreuzy, J Heath, A Bothmer, D Reyon, A Dass, E Marco, J Wilheim, ... MOLECULAR THERAPY 26 (5), 97-98, 2018 | 1 | 2018 |
| Resolve AML 001: An Adaptive Open-Label Multicentre Phase 1/2 Trial, to Determine the Recommended Phase 2 Dose of Cctx-001, and to Assess Safety, Tolerability, and Clinical … M Subklewe, N Boissel, S Mielke, P Barba, E Sala, E Deconinck, O Fiere, ... Blood 144, 2883.2, 2024 | | 2024 |
| IL-1RAP Is a Targetable Surface Antigen in Relapsed/Refractoy AML M Sabbah, M Fontaine, K Pacchiardi, A Delabrière, S De Botton, ... Blood 144, 4311, 2024 | | 2024 |
